Item 2.02 Results of Operations and Financial Condition. On March 3, 2026, STAAR Surgical Company (the “ Company”) published a press release reporting its financial results for the quarter and year ended January 2, 2026, a copy of which is furnished as Exhibit 99.1 to this report and is incorporated herein by this reference.

Item 7.01 Regulation FD Disclosure. During a conference call and webcast scheduled to be held at 5:30 p. m. Eastern / 2:30 p. m. Pacific on March 3, 2026, the Company’s Interim Co-Chief Executive Officer, President and Chief Operating Officer and the Company's Interim Co-Chief Executive officer and Chief Financial Officer will discuss the Company’s results for the quarter and year ended January 2, 2026. The Company’s shareholder letter for the conference call is furnished as Exhibit 99.2 to this Current Report. The information furnished herewith pursuant to Items 2.02 and 7.01 of this Current Report, including Exhibits 99.1 and 99.2, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”), or otherwise subject to the liabilities of that section. The information in Items 2.02 and 7.01 of this Current Report shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, regardless of any general incorporation language in the filing.

Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 99.1 Press release of the Company dated March 3, 2026. 99.2 Shareholder letter of the Company dated March 3, 2026. ───────────────────────────────────────────────────────────────────────────────────────────────── 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. STAAR Surgical Company March 3, 2026 /s/ DEBORAH ANDREWS Deborah Andrews Interim Co-Chief Executive Officer and Chief Financial Officer